TG Therapeutics, Inc. $TGTX Shares Acquired by Intech Investment Management LLC

Intech Investment Management LLC grew its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 116.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 153,132 shares of the biopharmaceutical company’s stock after purchasing an additional 82,253 shares during the quarter. Intech Investment Management LLC owned approximately 0.10% of TG Therapeutics worth $4,565,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Danske Bank A S acquired a new stake in shares of TG Therapeutics in the third quarter valued at approximately $25,000. Optiver Holding B.V. boosted its position in TG Therapeutics by 3,485.7% during the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 732 shares during the last quarter. Bessemer Group Inc. boosted its position in TG Therapeutics by 117.1% during the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 486 shares during the last quarter. Hantz Financial Services Inc. boosted its position in TG Therapeutics by 82.7% during the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 560 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in TG Therapeutics by 86.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 573 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TGTX has been the topic of a number of analyst reports. JPMorgan Chase & Co. decreased their target price on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of TG Therapeutics in a research report on Wednesday, May 27th. Wall Street Zen lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings upgraded shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. Finally, Zacks Research lowered shares of TG Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, TG Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $52.50.

TG Therapeutics Price Performance

Shares of TGTX opened at $37.94 on Monday. The firm has a market cap of $5.81 billion, a PE ratio of 13.27 and a beta of 1.68. The company’s fifty day moving average is $36.21 and its two-hundred day moving average is $32.32. TG Therapeutics, Inc. has a fifty-two week low of $25.28 and a fifty-two week high of $44.65. The company has a quick ratio of 5.12, a current ratio of 5.81 and a debt-to-equity ratio of 1.28.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The company had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The firm’s revenue for the quarter was up 69.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.03 EPS. Analysts forecast that TG Therapeutics, Inc. will post 1.31 earnings per share for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.